Chia Tai Tianqing Pharmaceutical Group Co., Ltd
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Chia Tai Tianqing Pharmaceutical Group Co., Ltd
Daiichi Sankyo obtains rights to antiemetic Nasea and the anti-hypertension drugs Perdipine and Oldeca. Mitsubishi Tanabe licenses Asian rights to Viela’s inebilizumab for a rare eye disorder.
Two years after its first big Navacim-based tie-up with Novartis, Parvus could earn beyond $800m in autoimmune R&D pact with Genentech. Iconic licenses ADC tech from Zymeworks, then out-licenses lead candidate to Exelixis.
After the recent approval of its first all-oral hepatitis C regimen, the China FDA is striving to approve within a year more direct-acting antiviral (DAA) therapies to treat all genotypes of the disease, setting the stage for both multinational and domestic pharma firms to compete in the world’s largest HCV drug market.
As predicted by Scrip last July, WuXi AppTec has moved one step closer to spinning out its biologics unit through an IPO on the Hong Kong equity market, while its main business unit is also proceeding with plans for a China domestic relisting.
- Generic Drugs
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
- Other Names / Subsidiaries
- CTTQ PHARMA
- Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. (CTTQ)